Please ensure Javascript is enabled for purposes of website accessibility

This Top Marijuana Stock Has Made It to Wall Street -- Is It Time to Buy?

By Keith Speights - May 27, 2018 at 9:32AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

You can now buy Canopy Growth on the NYSE. But should you?

Canopy Growth Corporation (CGC -18.57%) claims the biggest market cap of any marijuana stock on the planet. It's not even a close contest. Canopy's market cap of around $6 billion is more than $1.5 billion higher than the second-biggest marijuana stock.

Until now, Canopy Growth stock has been listed only on the Toronto Stock Exchange (TSX). However, the Canadian marijuana grower began trading on the New York Stock Exchange (NYSE) on Thursday. Canopy will also continue to be listed on the TSX under the ticker symbol "WEED." Now that this top marijuana stock has made it to Wall Street, is Canopy Growth a buy? 

Wall Street sign in front of New York Stock Exchange building.

Image source: Getty Images.

Does the NYSE listing matter?

Trading on the NYSE is a significant move for Canopy Growth. CEO Bruce Linton stated that Canopy's listing on the NYSE "will represent a continuation of our upward trajectory as we build the global cannabis industry." He's right. It's yet another step toward legitimization of the entire industry in which Canopy Growth has been a pioneer. 

On a practical note, listing on the NYSE also could provide exposure for Canopy to a much larger investing audience. The NYSE is the largest stock exchange in the world. The total combined market cap of stocks listed on the exchange is nearly seven times that of the TSX where Canopy is listed now.

Could inclusion on the NYSE automatically provide a boost to Canopy stock? Perhaps. On Feb. 27, 2018, Cronos Group (CRON -2.08%) became the first Canadian marijuana grower to list on any U.S. stock exchange when it began trading on the Nasdaq. Cronos stock enjoyed a big double-digit percentage jump the same week, with no other news serving as a catalyst.

So far, though, Canopy Growth hasn't experienced a similar bounce. One potential reason why: The stock had already moved nearly 20% higher since Canopy announced its application for listing on the NYSE. 

Good timing

The timing of Canopy Growth's move to the NYSE is really good. Something big is about to happen for Canadian marijuana stocks. Thanks to its anticipated listing on the NYSE, Canopy could be especially poised to benefit from this development.

I'm referring, of course, to the possibility that Canada will soon legalize the recreational use of marijuana. The Canadian Senate is scheduled for a full vote on legalization on June 7. There's a very good chance that the bill will pass. In March, the Senate voted 44-29 in favor of advancing the recreational marijuana legislation to committee review, with Canopy and other leading marijuana stocks jumping on the news.

Just how big could the Canadian recreational market be? The country's Parliamentary Budget Officer (PBO), which performs a similar function as the Congressional Budget Office in the U.S., estimated that marijuana sales would be between CA$4.2 billion and CA$6.2 billion in the first year of the legalization of recreational cannabis. The midpoint of that range is roughly US$4 billion.

However, based on marijuana sales in Colorado, it's not unreasonable to think that the Canadian marijuana market, including both medical and recreational cannabis, could grow to more than US$10 billion within a few years. Canopy Growth could realistically be looking at annual revenue of several billion dollars in the not-too-distant future.

Is Canopy Growth a buy?

Like many, I see Canopy Growth as the cream of the crop with Canadian marijuana stocks. But that by itself doesn't mean the stock is a smart pick right now.

There are two perspectives on Canopy Growth that investors should consider. One is that the stock is overpriced even with its growth prospects factored in. The other perspective is that Canopy's growth potential is so enormous that the stock still has plenty of room to run.

I'm in the latter camp. My take is that the global medical marijuana market should become much larger than the total marijuana market in Canada. I also expect that U.S. federal laws will be changed within a few years to allow state laws on marijuana to reign supreme. The bottom line is that I think the total worldwide marijuana market will be great enough that Canopy Growth will flourish.

But I could be wrong. Another alternative is that my predictions are right, but it takes a lot longer than expected for the global marijuana market to expand. In either of these scenarios, Canopy Growth would likely be a losing investment.

One thing that I'm confident about, though, is that if the marijuana market does grow dramatically, Canopy Growth will be one of the top leaders in the industry -- just like you'd expect from the first marijuana stock to be listed on the NYSE.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Canopy Growth Stock Quote
Canopy Growth
CGC
$2.85 (-18.57%) $0.65
Cronos Group Stock Quote
Cronos Group
CRON
$2.82 (-2.08%) $0.06

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
317%
 
S&P 500 Returns
112%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 07/01/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.